Evidence map›Paper›PMID 41929629›Full record

ArticleFrontiers in cell and developmental biology2026

Multi-omics analysis identifies CLDN10 as a B-cell-associated prognostic biomarker in HPV-negative head and neck squamous cell carcinoma.

Qihua Dang, Yayun He, Runan Zhao, Hongyuan Chen, Lijuan Yin, Yanhua Lu, Xiaocheng Shi, Yiming Li, Yanhua Chen, Yisha Gao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qihua Dang *Department of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Yayun He *Department of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Runan ZhaoDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Hongyuan ChenDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Lijuan YinDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Yanhua LuDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Xiaocheng ShiDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Yiming LiDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Yanhua ChenDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Yisha GaoDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.
Miaoxia HeDepartment of Pathology, Changhai Hospital, Naval Military Medical University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The prognosis of head and neck squamous cell carcinoma (HNSC) is poor, and new biomarkers are urgently needed. Claudin 10 (CLDN10) plays an important role in various tumors, but its function in HNSC remains unclear. Methods: Through bioinformatics analysis and experimental verification, the expression, prognostic value, and immunological correlation of CLDN10 in HNSC were systematically evaluated. Results: CLDN10 is downregulated in human papillomavirus negative HNSC, and its low expression is significantly associated with a decreased overall survival of patients, and it is an independent prognostic factor. Functional enrichment analysis shows that CLDN10 and its co-expressed genes are mainly enriched in B-cell-related immune pathways. Further analysis indicates that the expression level of CLDN10 is strongly correlated with the degree of B-cell infiltration in HNSC. Conclusion: The downregulation of CLDN10 is associated with poor prognosis in HNSC, especially in HPV-negative patients, and it has significant prognostic value. Its mechanism of action may involve the regulation of B-cell-mediated tumor immune response, providing potential targets for immunotherapy and prognosis assessment of HNSC.

Indexed as

B cellsbioinformaticsCLDN10hNSCHPVprognosis

Identifiers

PMID41929629
PMCPMC13040358

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.